Descripción del proyecto
Un dispositivo láser seguro mata biopelículas bacterianas en heridas crónicas
Actualmente, no existen métodos para erradicar las biopelículas bacterianas que se forman en las heridas crónicas, lo cual impide una rápida cicatrización en una cifra estimada de 10 millones de personas en Europa y 6,4 millones en los Estados Unidos. El proyecto LASER-HEAL quiere subsanar esta deficiencia mediante un dispositivo que llega a lo profundo de las heridas e incluye un «software» que reconoce y ayuda a situar el láser de forma precisa. Esta tecnología no invasiva emplea doce tratamientos de media hora de 1 000 euros cada uno y no daña las células cutáneas. El objetivo es desarrollar primero una clientela a través de clínicas estadounidenses, para luego expandirse a Europa y todo el mundo.
Objetivo
Chronic wounds affect 10M in Europe and 6.4 million people in the US, with annual costs of >€72Bn in Europe and >€22 Bn in the US. It is a silent epidemic. Key to this problem is the lack of truly effective solutions that fully eradicate bacteria-protecting biofilms deep within chronic wounds.
We have a game-changing new solution to tackle this problem: LASER-HEAL. LASER-HEAL is a medical device that consists of 1) a laser-generating unit that can reach deep within wounds; 2) optomechatronics to move the laser in a controlled manner and 3) software to recognize the contours and depth of wounds. LASER-HEAL enables, for the first time, non-invasive, safe, low-cost (€1.000 p/treatment), rapid (30 mins/session, total ~12) treatment, compatible with standard of care. We have preliminary data showing killing of all relevant species of bacteria, while human skin cells are left intact.
We will bring LASER-HEAL to the global wound care management market (€29bn in 2017 expected to reach €39bn by 2024). We will respond to the need of this market by delivering an effective antibiofilm device for chronic wounds. We will commercialize LASER-HEAL through sales to US clinics first, through fast FDA approval and confirm willingness to pay. By 2025, we will demonstrate revenue potential for LASER-HEAL, and seek a commercial exit, through acquisition (preferred) by a major medical device company, who will then bring LASER-HEAL to the European and global markets. Cumulative income of €75 million is predicted for LASER-HEAL by 2025 during this phase.
We have a unique proposition, backed by preliminary results and the interest of a major wound care company (confidential for this abstract). We want to undertake a detailed study to map successful market introduction for LASER-HEAL. Funding from SMEi Phase can support us with obtaining crucial market, regulatory and de-risked development informa
Ámbito científico
- natural sciencescomputer and information sciencessoftware
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- natural sciencesphysical sciencesopticslaser physics
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
VANLOSE
Dinamarca
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.